We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Improvement in Baroreflex Sensitivity in OSAS

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00284037
Recruitment Status : Unknown
Verified May 2005 by Nagoya University.
Recruitment status was:  Recruiting
First Posted : January 31, 2006
Last Update Posted : January 31, 2006
Sponsor:
Information provided by:

Study Description
Brief Summary:
Individuals with obstructive sleep apnea syndrome (OSAS) are at high risk for cardiovascular morbidity and mortality. The effect of long-term nocturnal therapy with continuous positive airway pressure (CPAP) on daytime baroreflex sensitivity (BRS), a predictor of cardiac death, was investigated in OSAS patients.

Condition or disease Intervention/treatment
Obstructive Sleep Apnea Syndrome Device: continuous positive airway pressure therapy

Study Design

Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Sleep Apnea
U.S. FDA Resources

Arms and Interventions


Outcome Measures

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • obstructive sleep apnea syndrome

Exclusion Criteria:

  • diabetes mellitus, chronic obstructive lung disease, coronary or valvular heart disease, congestive heart failure, renal failure, or endocrine dysfunction. Moreover, none of them were taking b-blockers, vasodilators, or inotropic agents at the time of enrollment in the study.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00284037


Contacts
Contact: Akiko Noda, PhD +81-52-719-1537 a-noda@met.nagoya-u.ac.jp

Locations
Japan
Nagoya University of Health Sciences Recruiting
Nagoya, Japan, 461-8673
Contact: Akiko Noda, PhD    +81-719-1537    a-noda@met.nagoya-u.ac.jp   
Principal Investigator: Akiko Noda, PhD         
Sponsors and Collaborators
Nagoya University
Investigators
Study Chair: Mitsuhiro Yokota, MD.PhD Department of Cardiovascular Genome Science, Nagoya University School of Medicine, Nagoya, Aichi, Japan
More Information

ClinicalTrials.gov Identifier: NCT00284037     History of Changes
Other Study ID Numbers: NU-06-A-0003
First Posted: January 31, 2006    Key Record Dates
Last Update Posted: January 31, 2006
Last Verified: May 2005

Keywords provided by Nagoya University:
obstructive sleep apnea,
baroreceptors

Additional relevant MeSH terms:
Sleep Apnea Syndromes
Sleep Apnea, Obstructive
Apnea
Respiration Disorders
Respiratory Tract Diseases
Sleep Disorders, Intrinsic
Dyssomnias
Sleep Wake Disorders
Nervous System Diseases